导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -13.59% | 79/158 |
| 近一周 | -2.60% | 39/164 |
| 近一月 | -2.46% | 60/164 |
| 近一季 | -3.09% | 60/164 |
| 近半年 | -8.41% | 78/160 |
| 近一年 | -18.90% | 69/155 |
| 近两年 | 27.56% | 68/130 |
| 近三年 | 20.77% | 45/100 |
| 成立以来 | -7.57% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-9.35% 259/360 |
-11.04% 286/366 |
- - |
- - |
| 2025 | 21.64% 99/358 |
16.77% 85/340 |
0.56% 229/348 |
12.90% 121/354 |
-8.24% 237/358 |
| 2024 | 29.04% 21/329 |
0.25% 9/12 |
- - |
20.71% 78/318 |
-2.03% 172/329 |
| 2023 | -14.42% 178/275 |
0.26% 156/205 |
-3.35% 141/230 |
-5.98% 177/262 |
-6.07% 241/276 |
| 2022 | -11.13% 48/201 |
-11.10% 95/153 |
9.02% 38/164 |
-18.17% 115/189 |
12.06% 84/202 |
| 2021 | -26.07% 93/150 |
0.62% 184/312 |
-3.30% 287/328 |
-17.76% 294/358 |
-7.61% 101/151 |
| 2020 | -5.86% 61/103 |
-12.19% 149/280 |
3.47% 250/295 |
-4.03% 254/299 |
7.97% 156/305 |
| 2019 | 13.34% 57/88 |
10.03% 122/258 |
-0.73% 197/268 |
-3.27% 208/253 |
7.27% 111/266 |
| 2018 | -7.88% 37/79 |
- - |
- - |
- - |
-8.45% 100/241 |
| 2017 | 18.40% 31/69 |
- - |
- - |
- - |
- - |
| 2016 | 3.48% 36/59 |
- - |
- - |
- - |
- - |
| 2015 | -21.36% 40/49 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 广发中证香港创新药ETF(QDII) | 1.2744 | 27.49% |
| 广发道琼斯石油指数美元现汇A | 0.4802 | 27.44% |
| 广发道琼斯石油指数美元现汇C | 0.4718 | 27.38% |
| 广发道琼斯石油指数(QDII-LOF)美元现汇E | 0.4729 | 27.33% |
| 广发道琼斯石油指数人民币A | 3.2498 | 26.68% |
| 广发道琼斯石油指数人民币C | 3.1927 | 26.58% |
| 广发道琼斯石油指数(QDII-LOF)人民币E | 3.2003 | 26.55% |
| 广发中证香港创新药ETF发起式联接(QDII)C | 1.3286 | 26.01% |
| 富国标普石油天然气勘探及生产精选行业ETF(QDII) | 1.4105 | 25.68% |
| 汇添富恒生生物科技ETF(QDII) | 1.1055 | 25.31% |
| 银华恒生中国企业指数 VS. 建信富时100指数(QDII)人民币A(539003) |